ABB Ltd (ABBNY) Spending and interest coverage
- R&D / revenue · 12 months: Value 4.09%; Formula and calculation Research and development expense / revenue. Period ending 2023-12-31..
- Stock-based compensation / revenue · 12 months: Value 0.32%; Formula and calculation Share-based compensation / revenue. Period ending 2023-12-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2023-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 4.09% | Research and development expense / revenue. Period ending 2023-12-31. $1.32B ÷ $32.23B × 100 ≈ 4.09% |
| Stock-based compensation / revenue · 12 months | 0.32% | Share-based compensation / revenue. Period ending 2023-12-31. $103.00M ÷ $32.23B × 100 ≈ 0.32% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 1.32B USD | Research and Development Expense |
| Revenue | 32.23B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 103.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 4.87B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $1.32B | $32.23B | $103.00M | $4.87B | (m) | 4.09% | 0.32% | (m) | (m) |
| 2022-12-31 | $1.17B | $29.45B | $42.00M | $3.34B | (m) | 3.96% | 0.14% | (m) | (m) |
| 2021-12-31 | $1.22B | $28.95B | $59.00M | $5.72B | (m) | 4.21% | 0.20% | (m) | (m) |
| 2020-12-31 | $1.13B | $26.13B | $44.00M | $1.59B | (m) | 4.31% | 0.17% | (m) | (m) |
| 2019-12-31 | $1.20B | $27.98B | $46.00M | $1.94B | (m) | 4.28% | 0.16% | (m) | (m) |
| 2018-12-31 | $1.15B | $27.66B | $50.00M | $2.23B | (m) | 4.15% | 0.18% | (m) | (m) |
| 2017-12-31 | $1.36B | $34.31B | $58.00M | $3.43B | (m) | 3.98% | 0.17% | (m) | (m) |
| 2016-12-31 | $1.30B | $33.83B | $54.00M | $2.99B | (m) | 3.84% | 0.16% | (m) | (m) |
| 2015-12-31 | $1.41B | $35.48B | (m) | $3.05B | (m) | 3.96% | (m) | (m) | (m) |
| 2014-12-31 | $1.50B | $39.83B | (m) | $4.18B | (m) | 3.76% | (m) | (m) | (m) |
| 2013-12-31 | $1.47B | $41.85B | (m) | $4.39B | (m) | 3.51% | (m) | (m) | (m) |
| 2012-12-31 | $1.46B | $39.34B | (m) | $4.06B | (m) | 3.72% | (m) | (m) | (m) |
| 2011-12-31 | $1.37B | $37.99B | (m) | $4.67B | (m) | 3.61% | (m) | (m) | (m) |
| 2010-12-31 | $1.08B | $31.59B | (m) | $3.82B | (m) | 3.43% | (m) | (m) | (m) |
| 2009-12-31 | (m) | $31.80B | (m) | $4.13B | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $34.91B | (m) | $4.55B | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | $29.18B | (m) | $4.02B | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.